6/21/2026

Janusmed sex and gender

Janusmed sex and gender – Flucloxacillin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Flucloxacillin

Flucloxacillin

Class : B

Show all info

Print

Contact us

  1. Wing K, Bhaskaran K, Pealing L, et al. Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study. J Antimicrob Chemother. 2017;72(9):2636-2646.

  2. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15:154-61.

  3. Fairley CK, Boyd I, Purcell P, McNeil J. Flucloxacillin jaundice. Lancet. 1992;339:679.

  4. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP, DILIGEN Study., International SAE Consortium.. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009 Jul;41(7):816-9

  5. Lindh M, Hallberg P, Yue QY, Wadelius M. Clinical factors predicting drug-induced liver injury due to flucloxacillin. Drug Healthc Patient Saf. 2018;10:95-101.

  6. Leegwater E, Westgeest AC, Schippers EF, Wilms EB, van Nieuwkoop C, Visser LE. Hypokalaemia in patients treated with intravenous flucloxacillin: Incidence and risk factors. Br J Clin Pharmacol. 2022;88(6):2938-2945.

  7. van der Heijden C, Duizer ML, Fleuren H, et al. Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia. Br J Clin Pharmacol. 2019;85(12):2886-2890.

  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Wing K, Bhaskaran K, Pealing L, et al. Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study. J Antimicrob Chemother. 2017;72(9):2636-2646.
  2. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15:154-61.
  3. Fairley CK, Boyd I, Purcell P, McNeil J. Flucloxacillin jaundice. Lancet. 1992;339:679.
  4. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP, DILIGEN Study., International SAE Consortium.. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009 Jul;41(7):816-9
  5. Lindh M, Hallberg P, Yue QY, Wadelius M. Clinical factors predicting drug-induced liver injury due to flucloxacillin. Drug Healthc Patient Saf. 2018;10:95-101.
  6. Leegwater E, Westgeest AC, Schippers EF, Wilms EB, van Nieuwkoop C, Visser LE. Hypokalaemia in patients treated with intravenous flucloxacillin: Incidence and risk factors. Br J Clin Pharmacol. 2022;88(6):2938-2945.
  7. van der Heijden C, Duizer ML, Fleuren H, et al. Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia. Br J Clin Pharmacol. 2019;85(12):2886-2890.
  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]